FDA approves Bristol Myers Squibb’s Sotyktu for adults with active psoriatic arthritis

Reuters10:59
FDA approves Bristol Myers Squibb’s Sotyktu for adults with active psoriatic arthritis

The U.S. FDA approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. The approval was based on results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 trials evaluating Sotyktu 6 mg once daily. In PsA-1, 54% of patients on Sotyktu achieved ACR20 at Week 16 versus 34% on placebo. In PsA-2, 54% of patients on Sotyktu achieved ACR20 at Week 16 versus 39% on placebo. More information is available from Bristol Myers Squibb.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260306816774) on March 07, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment